MultiValent Biotherapies is developing a peptide-like drug conjugate that hits two validated targets to treat prostate cancer ...
First closing of $27 million Series A financing - - Fundingwill support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results